DPP-Ⅳ抑制剂与二甲双胍联用对2型糖尿病的临床疗效观察

Clinical observation of dipeptidyl-peptidase Ⅳ inhibitor combined with metformin on treatment of patients with type 2 diabetes

目的:探讨DPP-Ⅳ抑制剂联用二甲双胍对2型糖尿病的疗效。方法:将某医院90例2型糖尿病患者分为三组。对照组30例:单用二甲双胍治疗;治疗组A 30例:用磷酸西格列汀与二甲双胍联合治疗;治疗组B 30例:用利格列汀与二甲双胍联合治疗,疗程12周。比较治疗前后空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1c)、体重指数(BMI)、空腹胰岛素(FIns)的变化。结果:治疗12周后对照组FBG、2h PG、Hb A1c、BMI、FIns分别为:(7.6±1.8)mmol/L;(10.6±1.8)mmol/L;(7.3±1.7)%;(24.3±1.7)kg/㎡;(10.6±1.1)μU/m L。治疗组A分别为:(6.3±1.7)mmol/L;(8.8±1.8)mmol/L;(6.7±1.3)%;(23.4±1.0)kg/㎡;(11.7±1.1)μU/m L。治疗组B分别为:(6.5±1.4)mmol/L;(8.6±1.6)mmol/L;(6.5±1.4)%;(24.1±1.2)kg/㎡;(11.2±1.1)μU/m L。三组均较治疗前明显下降(P<0.01),治疗组A、B明显优于对照组(P<0.05)。结论:DPP-Ⅳ抑制剂联用二甲双胍对2型糖尿病疗效确切。

Objective To observe the clinical effect and safety of dipeptidyl-peptidase IV inhibitor and mefformin in the treatment of patients with type 2 diabetes.Methods：90 cases of patients with type 2 diabetes were randomly divided into the treatment group A （30 cases） ;treatment group B （30 cases）and the control group （30 cases）.The patients in control group were given metformin,those in treatment group were given metformin combined with dipeptidyl-peptidase IV inhibitor.After 12 weeks treatment,the changes of FBG, 2hPBG,HbAlc, BMI , Fins was observed in three groups.Results： After 12 weeks treatment,the level of FBG,2hPBG, HbAlc, BMI , Fins in the control group treatment group was （7.6±1.8）mmol/L; （ 10.6±1.8）mmol/L; （7.3±1.7）% ; （24.3±1.7）kg/m^2 ; （ 10.6±1.1 ）μU/mL respectively,in treatment group was （6.3±1.7）mmol/L; （8.8±1.8）mmol/L; （6.7±1.3）%; （23.4±1.0）kg/m^2 ; （11.7±1.1）μU/mL ; （6.5±1.4） mmol/L; （8.6±1.6）mmol/L; （6.5±1.4）%; （24.1±1.2）kg/m^2 ; （11.2±1.1）μU/mL respectively,significantly deceased compared with before treatment （P〈0.01）;and the treatment group A, B were better than that of control group （P〈0.05）.Conclusion：It is safe and effective in treating patients with type,2 diabetes with dipeptidyl-peptidase IV inhibitor combined with mefformin.